0000000000965689

AUTHOR

C Torti

showing 4 related works from this author

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease in…

2011

Abstract Background Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce. Methods Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after…

AdultCD4-Positive T-LymphocytesMalemedicine.medical_treatmentProtease InhibitorHuman immunodeficiency virus (HIV)CD4+ T-cellHIV InfectionsBiologymedicine.disease_causeSettore MED/17 - MALATTIE INFETTIVENucleoside Reverse Transcriptase InhibitorTimelcsh:Infectious and parasitic diseasesZidovudineRetrospective Studieimmune system diseasesAntiretroviral Therapy Highly ActivemedicineHumansProtease inhibitor (pharmacology)HIV InfectionProtease Inhibitorslcsh:RC109-216Retrospective StudiesHIV; CD4+ T-cellProteaseCd4 t cellDrug SubstitutionBackground dataHIVvirus diseasesMiddle AgedVirologyHIV; AIDS; CD4; NRTIReverse Transcriptase InhibitorCD4 Lymphocyte CountInfectious DiseasesCD4-Positive T-LymphocyteReverse Transcriptase InhibitorsRitonavirFemaleAdult; Antiretroviral Therapy Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Time; Drug Substitution; Infectious Diseasesmedicine.drugHumanResearch Article
researchProduct

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

2011

Background and objectives: Guidelines indicate a plasma HIV-1 RNA load of 500-1000 copies/mL as the minimal threshold for antiretroviral drug resistance testing. Resistance testing at lower viral load levels may be useful to guide timely treatment switches, although data on the clinical utility of this remain limited. We report here the influence of viral load levels on the probability of detecting drug resistance mutations (DRMs) and other mutations by routine genotypic testing in a large multicentre European cohort, with a focus on tests performed at a viral load <1000 copies/mL. Methods: A total of 16511 HIV-1 reverse transcriptase and protease sequences from 11492 treatment-experienced …

MaleDrug ResistanceHIV InfectionsDrug resistanceCohort Studies0302 clinical medicineGenotypeHIV InfectionPharmacology (medical)030212 general & internal medicineViral0303 health sciencesProteolytic enzymesGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; RNA Viral; Viral Proteins; Drug Resistance Viral; Mutation Missense; Viral Load; Pharmacology; Pharmacology (medical); Infectious DiseasesViral LoadGenotypic testing3. Good healthEuropeInfectious DiseasesCohortRNA ViralFemaleViral loadCohort studyHumanMicrobiology (medical)AdultGenotypeAnti-HIV AgentsMutation MissenseBiologySettore MED/17 - MALATTIE INFETTIVE03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingDrug Resistance ViralHumansViral ProteinPharmacology030306 microbiologyHIVAnti-HIV AgentVirologyReverse transcriptaseCD4 Lymphocyte CountRegimenHIV; genotypic testing; viral loadGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation Missense; RNA Viral; Viral Load; Viral ProteinsImmunologyMutationHIV-1RNAMissenseCohort Studie
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct